Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles

British Journal of Clinical Pharmacology

Volumn 69, Issue 6, 2010, Pages 593-597

  Yamazaki, Hiroshi ^a   Nakamoto, Minako ^a   Shimizu, Makiko ^a   Murayama, Norie ^a   Niwa, Toshiro ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

CYP3A4; CYP3A5; Drug interaction; Genetic polymorphism; Thalidomide; Voriconazole

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FLUCONAZOLE; ITRACONAZOLE; MIDAZOLAM; PROTEINASE INHIBITOR; RECOMBINANT ENZYME; SAQUINAVIR; THALIDOMIDE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ALLELE; ALTERNATIVE HYPOTHESIS; AREA UNDER THE CURVE; ARTICLE; CATALYSIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; LIVER MICROSOME METABOLISM; PHARMACOGENETICS; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MICROSOMES, LIVER; PYRIMIDINES; TRIAZOLES;

EID: 77952016964     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03656.x     Document Type: Article

References (25)

1. Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol 2008 21 : 70 83.
2. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994 270 : 414 423. (Pubitemid 24229655)
3. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokin Biopharm 1996 24 : 475 490.
4. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001 27 : 383 391. (Pubitemid 32268418)
5. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Saito T, Parkinson A, Nakagawa K, Kamataki T. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers. Xenobiotica 2005 35 : 69 83. (Pubitemid 40459218)
6. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T. CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 2004 19 : 120 129.
7. deWildt SN, Kearns GL, Leeder JS, vandenAnker JN. Glucuronidation in humans -pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999 36 : 439 452.
8. Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 2006 45 : 13 31.
9. Koltin Y, Hitchcock CA. The search for new triazole antifungal agents. Curr Opin Chem Biol 1997 1 : 176 182. (Pubitemid 127437142)
10. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998 50 : 387 411. (Pubitemid 28477680)
11. Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 2004 57 : 473 486. (Pubitemid 38519653)
12. Niwa T, Murayama N, Emoto C, Yamazaki H. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr Drug Metab 2008 9 : 20 33. (Pubitemid 351201667)
13. Niwa T, Murayama N, Yamazaki H. Heterotropic cooperativity in oxidation mediated by cytochrome P450. Curr Drug Metab 2008 9 : 453 462. (Pubitemid 352025198)
14. Okada Y, Murayama N, Yanagida C, Shimizu M, Guengerich FP, Yamazaki H. Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5. Drug Metab Dispos 2009 37 : 18 23.
15. Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J, Gotoh Y, Iwatsubo T, Kanamitsu S, Kato M, Kawahara I, Niinuma K, Nishino A, Sato N, Tsukamoto Y, Ueda K, Itoh T, Sugiyama Y. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 2002 4 : E25. (Pubitemid 36034978)
16. Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H. Roles of CYP3A4 and CYP2C19 in methylhydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol 2007 73 : 2020 2026. (Pubitemid 46677908)
17. Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 1999 27 : 180 187.
18. Isoherranen N, Ludington SR, Givens RC, Lamba JK, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Thummel KE, Paine MF. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate dependent: an in vitro-in vivo evaluation. Drug Metab Dispos 2008 36 : 146 154.
19. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006 316 : 336 348. (Pubitemid 41832613)
20. Galetin A, Ito K, Hallifax D, Houston JB. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 2005 314 : 180 190. (Pubitemid 41058254)
21. Racha JK, Zhao ZS, Olejnik N, Warner N, Chan R, Moore D, Satoh H. Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. Drug Metab Pharmacokinet 2003 18 : 128 138.
22. Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004 32 : 1121 1131. (Pubitemid 39287586)
23. Turpeinen M, Uusitalo J, Jalonen J, Pelkonen O. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci 2005 24 : 123 132. (Pubitemid 40051295)
24. Di L, Kerns EH, Li SQ, Carter GT. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. Int J Pharm 2007 335 : 1 11. (Pubitemid 46482859)
25. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002 46 : 3091 3093.